Device Trial Radar · NCT07948200
Urinary DNA Methylation Testing (Bladder EpiCheck®) and Its Peri-operative Kinetics for the Prediction of Residual Disease at Second Transurethral Resection in T1 Non-muscle-invasive Bladder Cancer
Last checked: Nov 19, 2026Latest source record: Nov 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
60
Planned (sponsor's estimate)
Start
Jan 31, 2027
Primary completion
Jan 31, 2029
Study completion Jan 31, 2029
Sponsor
- Lead sponsor
- Istituto Oncologico Veneto IRCCSAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Menarini Diagnostics s.r.l
- First posted
- Nov 19, 2026
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Diagnostic
- FDA-regulated device
- No
- Who can join
- All sexes, from 18 years, up to 99 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
European Association of Urology (EAU) guidelines mandate a second transurethral resection of bladder tumour (re-TURBt) for patients with high-grade or pT1 non-muscle-invasive bladder cancer (NMIBC) to eradicate residual disease and avoid understaging. However, 30% to 50% or more of patients undergoing re-TURBt have no residual tumour found upon re-resection, incurring surgical and anaesthetic risks, potential morbidity, healthcare costs, and delays in adjuvant therapy without direct oncological benefit. Current non-invasive triage tools, such as urine cytology and office cystoscopy, suffer from low sensitivity or diagnostic ambiguity due to ongoing post-operative inflammation and tissue healing in a recently resected bladder. While novel molecular biomarkers like Bladder EpiCheck® demonstrate high sensitivity and negative predictive value in the surveillance setting, single-timepoint measurements shortly after resection struggle to differentiate transient, healing-induced epigenetic changes from true persistent malignancy. Evaluating the longitudinal trajectory of the EpiScore across two distinct post-operative timepoints (T1 and T2) provides a physiological basis for distinguishing decaying inflammatory/reparative signals from stable or rising signals indicative of residual disease. Demonstrating the diagnostic accuracy of Bladder EpiCheck® at T2, alongside the dynamic change in EpiScore (\ΔEpiScore), will establish whether non-invasive urine biomarker testing can reliably select low-risk pT1 NMIBC patients in whom re-TURBt can be safely omitted.
Conditions
- Non-Muscle-Invasive Bladder Cancer
Interventions
Bladder EpiCheckDevice
The investigational IVD medical device evaluated as the index test is the Bladder EpiCheck® system (manufactured by Nucleix Ltd.; exclusive Italian distributor: A. Menarini Diagnostics s.r.l.). The assay is CE-IVD marked under Directive 98/79/EC (Annex III, General IVD category) and cleared by the US FDA via the 510(k) pathway. The manufacturer operates under a certified UNI CEI EN ISO 13485:2016 quality management system. Bladder EpiCheck® profiles the DNA methylation patterns of 15 proprietary DNA biomarkers on genomic DNA isolated from the cellular pellet of a voided urine sample. The assay protocol involves DNA extraction, digestion with a methylation-sensitive restriction enzyme, and subsequent multiplex real-time polymerase chain reaction (multiplex real-time PCR). Dedicated analysis software generates a quantitative integrative score termed the EpiScore, on a continuous scale from 0 to 100. In accordance with the manufacturer's Instructions for Use (IFU), the qualitative diagno
Primary outcomes
What the sponsor says the trial is designed to measure.
- Diagnostic accuracy of Bladder EpiCheck® test at timepoint T2 for residual disease at second TURBt in T1 NMIBC patients.Time frame: Through study completion, an average of 2 years
- Diagnostic accuracy of change EpiScore between the two subsequent timepoints T1 and T2.Time frame: Through study completion, an average of 2 years
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Istituto Oncologico Veneto
Padova, Italy/Padova, Italy
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.